Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya31231Editorial articleПередовая статьяReview ArticleBoceprevir: New possibilities for the antiviral treatment of chronic hepatitis CБоцепревир: новые возможности противовирусного лечения хронического гепатита СNikitinI GНикитинИ Гigor.nikitin.64@mail.ruBaĭkovaI EБайковаИ ЕGogovaL MГоговаЛ МVolynkinaV MВолынкинаВ МKisliakovV AКисляковВ АРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова Министерства здравоохранения Российской Федерации, Москва15022013852VOL 85, NO2 ()ТОМ 85, №2 (2013)768410042020Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/31231

The given clinical review covers current antiviral therapy for chronic hepatitis C. Traditional antiviral therapy with pegylated interferon-α and ribavirin in patients with chronic hepatitis C virus genotype 1 allows a sustained virological response (SVR) to be achieved in no more than 40% of the treated patients. The practical introduction of the third component of the therapy as direct-acting antiviral agents makes it possible to substantially increase SVR, on the one hand, and to reduce treatment time, on the other hand. This review carefully analyzes the results of clinical trials of boceprevir (a new direct-acting antiviral agent and an NS3 serine protease inhibitor) that, when incorporated into an antiviral therapy regimen with pegylated interferons and ribavirin, considerably improves treatment results in patients with chronic hepatitis C virus genotype 1. Also, it discusses the safety and tolerance of drugs that belong to the class of hepatitis C virus serine protease inhibitors, as well as the problem of viral resistance.

Аннотация. В представленном клиническом обзоре освещается проблема современной противовирусной терапии хронического гепатита С. Традиционное противовирусное лечение с использованием пегилированного α-интерферона и рибавирина у пациентов с хроническим гепатитом С, инфицированных вирусом 1-го генотипа, позволяет достичь устойчивого вирусологического ответа (УВО) не более чем у 40% пролеченных пациентов. Внедрение в практику третьего компонента терапии в виде прямых противовирусных агентов, с одной стороны, позволяет существенно повысить УВО, с другой - сократить сроки лечения пациента. В представленном обзоре тщательно проанализированы результаты клинических исследований по препарату боцепревир (прямой противовирусный агент - ингибитор сериновой NS3-протеазы), который при включении в схему противовирусной терапии пегилированными интерферонами и рибавирином существенно улучшает результаты терапии у пациентов с хроническим гепатитом С, инфицированных вирусом 1-го генотипа. Кроме того, обсуждены вопросы безопасности и переносимости препаратов, относящихся к классу ингибиторов сериновой протеазы вируса гепатита С, а также проблема резистентности.

hepatitis C virusprotease inhibitorboceprevirviral resistanceвирус гепатита Сингибитор протеазыбоцепревирвирусная резистентностьTomas D.L. Hepatitis C. Epidemiologic quandaries. Clin Liver Dis 2001; 5 (4): 955-968.Verma E.C., Brown R.S. Jr. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006; 10 (4): 919-940.Lauer G., Walker B. Hepatitis C virus infection. N Engl J Med 2001; 345 (1): 41-52.Wasley A., Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20 (1): 1-16.Penin F., Dubuisson J., Rey F.A. et al. Structural biology of hepatitis C virus. Hepatology 2004; 39 (1): 5-19.Nielsen S.U., Bassendine M.F., Burt A.D. et al. Characterization of the genome and structural proteins of hepatitis C virus resolved from infected human liver. J Gen Virol 2004; 85 (Pt 6): 1497-1507.Pisarev A.V., Shirokikh N.E., Hellen C.U. Translation initiation by factor-independent binding of eukaryotic ribosomes to internal ribosomal entry sites. C R Biol 2005; 328 (7): 589-605.Lee G., Piper D.E., Wang Z. et al. Novel inhibitors of hepatitis C virus RNA-dependent RNA polymerases. J Mol Biol 2006; 357 (4): 1051-1057.Biswal В.К., Wang М., Cherney M.M. et al. Non-nucleoside inhibitors binding to hepatitis С virus NS5B polymerase reveal a novel mechanism of inhibition. J Mol Biol 2006; 361 (1): 33-45.Kunkel M., Lorinczi M., Rijnbrand R. et al. Self-assembly of nudeocapsid-like particles from recombinant hepatitis С virus core protein. J Virol 2001; 75 (5): 2119-2129.McHutchison J.G., Lawitz E.J., Shiffman M.L. et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis С infection. N Engl J Med 2009; 361 (6): 580-593.Manns M.P., McHutchison J.G., Gordon S.C. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358 (9286): 958-965.Fried M.W., Shiffman M.L., Reddy K.R. et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis С virus infection. N Engl J Med 2002; 347 (13): 975-982.Sulkowski M. Treatment of hepatitis С in HIV-infected persons: a work in progress. J Hepatol 2008; 48 (1): 5-7.Conjeevaram H.S., Fried M.W., Jeffers U. et al. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis С genotype 1. Gastroenterology 2006; 131 (2): 470-477.Muir A.J., Bornstein J.D., Killenberg P.G. et al. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis С in blacks and non-Hispanic whites [see comment] [Erratum appears in N Engl J Med 2004; 351 (12): 1268]. N Engl J Med 2004; 350 (22): 2265-2271.Mangia A., Minerva N., Bacca D. et al. Individualized treatment duration for hepatitis С genotype 1 patients: a randomized controlled trial. Hepatology 2008; 47 (1): 43-50.Bartenschlager R. Hepatitis С virus replicons: potential role for drug development. Nat Rev Drug Discov 2002; 1 (11): 911-916.Llinas-Brunet M., Bailey M.D., Bolger G. et al. Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis С virus NS3 protease leading to the discovery of BILN 2061. J Med Chem 2004; 47 (7): 1605-168.Steinkuhier C., Biasiol G., Brunetti M. et al. Product inhibition of the hepatitis С virus NS3 protease. Bio­chemistry 1998; 37 (25): 8899-8905.Ingallinella P., Altamura S., Bianchi E. et al. Potent peptide inhibitors of human hepatitis С virus NS3 protease are obtained by optimizing the cleavage products. Biochemistry 1998; 37 (25): 8906-8914.Lohmann V., KoErner F., Koch J. et al. Replication of subgenomic hepatitis С virus RNAs in a hepatoma cell line. Science 1999; 285 (5424): 110-113.Pause A., Kukolj G., Bailey M. et al. An NS3 serine protease inhibitor abrogates replication of subgenomic hepatitis С virus RNA. J Biol Chem 2003; 278 (22): 20 374-20 380.Hinrichsen H., Benhamou Y., Wedemeyer H. et al. Short-term antiviral efficacy of BILN 2061, a hepatitis С virus serine protease inhibitor, in hepatitis С genotype 1 patients. Gastroenterology 2004; 127 (5): 1347-1355.Lamarre D., Anderson P.C., Bailey M. et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis С virus. Nature 2003; 426 (6963): 186-189.Malcolm B.A., Liu R., Lahser F. et al. SCH 503034, a mechanism-based inhibitor of hepatitis С virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrob Agents Chemother 2006; 50 (3): 1013-1020.Sarrazin C., Rouzier R., Wagner F. et al. SCH 503034, a novel hepatitis С virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders [see comment]. Gastroenterology 2007; 132 (4): 1270-1278.Sarrazin C., Kieffer T.L., Bartels D. et al. Dynamic hepatitis С virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007; 132 (5): 1767-1777.Schiff E., Poordad E., Jacobson I. et al. Boceprevir (B) combination therapy in null responders (NR): response dependent on interferon responsiveness. J Hepatol 2008; 48: S46.Kwo P.Y., Lawitz E.J., McCone J. et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis С infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010; 376 (9742): 705-716.Sulkowski M., Shiffman M.L., Afdhal N.H. et al. Decline in hemoglobin is associated with sustained virologic response (SVR) among HCV genotype 1-infected persons treated with peginterferon (PEG)/ribavirin (RBV): analysis from the ideal study. Gastroenterology 2010; 139: 1602-1611.Poordad F., McCone J., Bacon B. et al. Boceprevir with peginterferon/ribavirin for untreated chronic hepatitis С N Engl J Med 2011; 364: 1195-1206.Bacon B., Gordon S., Lawitz E. et al. Boceprevir for treatment-resistant chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.